204 related articles for article (PubMed ID: 19723467)
21. Single annual injectable treatment for postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
[TBL] [Abstract][Full Text] [Related]
22. Denosumab: anti-RANKL antibody.
Miller PD
Curr Osteoporos Rep; 2009 Mar; 7(1):18-22. PubMed ID: 19239825
[TBL] [Abstract][Full Text] [Related]
23. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC
J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438
[TBL] [Abstract][Full Text] [Related]
24. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046
[TBL] [Abstract][Full Text] [Related]
25. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
26. [Osteoporosis treatment by anti-RANKL antibody].
Sugimoto T
Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
[TBL] [Abstract][Full Text] [Related]
27. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
28. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
29. Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.
Hossain M; Chowdhury IH; Emran MA; Habib AH; Asaduzzamnan AK; Alam M; Ferdous C
Bangladesh Med Res Counc Bull; 2010 Dec; 36(3):74-7. PubMed ID: 21548542
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on denosumab in postmenopausal osteoporosis.
Moen MD; Keam SJ
BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
[TBL] [Abstract][Full Text] [Related]
31. Denosumab--an emerging treatment for postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
[TBL] [Abstract][Full Text] [Related]
32. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Hochberg MC
Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
[TBL] [Abstract][Full Text] [Related]
33. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
34. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
35. Effect of osteoporosis treatment on mortality: a meta-analysis.
Bolland MJ; Grey AB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2010 Mar; 95(3):1174-81. PubMed ID: 20080842
[TBL] [Abstract][Full Text] [Related]
36. Osteoporosis in men: what has changed?
Adler RA
Curr Osteoporos Rep; 2011 Mar; 9(1):31-5. PubMed ID: 21113693
[TBL] [Abstract][Full Text] [Related]
37. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
[TBL] [Abstract][Full Text] [Related]
38. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
39. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
40. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]